 |
|
|
| |
Phase 2 Pharmacokinetics and Anti-Drug Antibody Results of the Investigational Twice-Yearly HIV-1 Treatment Regimen Lenacapavir,
Teropavimab, and Zinlirvimab
|
| |
| |
IDWeek 2025, October 19-22 2025, Atlanta, GA, USA
Nan Zhang*, Jianmin Li, Hui Liu, Kwad Mponponsuo, Sean E. Collins, Yanan Zheng
Gilead Sciences, Inc., Foster City, CA, USA.
*Presenting author
EACS2025: Efficacy and Safety of a Twice-Yearly Regimen of Lenacapavir, Teropavimab, and Zinlirvimab: Phase 2 Week 52 Results - (10/20/25)
|
| |
|
|
|
|
|
